Atezolizumab + Tiragolumab + Oxaliplatin + Capecitabine
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Stomach Neoplasms
Conditions
Stomach Neoplasms, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Trial Timeline
Aug 6, 2021 → Nov 17, 2023
NCT ID
NCT04933227About Atezolizumab + Tiragolumab + Oxaliplatin + Capecitabine
Atezolizumab + Tiragolumab + Oxaliplatin + Capecitabine is a phase 2 stage product being developed by Roche for Stomach Neoplasms. The current trial status is terminated. This product is registered under clinical trial identifier NCT04933227. Target conditions include Stomach Neoplasms, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04933227 | Phase 2 | Terminated |
Competing Products
20 competing products in Stomach Neoplasms